In the Q2, Beam Therapeutics Inc 's corporate clients experienced a reduction by -8.24 % in their costs of revenue, compared to a year ago, sequentially costs of revenue were trimmed by -10.07 %. During the corresponding time, Beam Therapeutics Inc saw a revenue deteriorated by -94.21 % year on year, sequentially revenue fell by -98.46 %. While revenue at the Beam Therapeutics Inc 's corporate clients recorded rose by 8.08 % year on year, sequentially revenue grew by 6.94 %.
Customers of Beam Therapeutics Inc saw their costs of revenue decrease by -8.24 % in Q2 compare to a year ago, sequentially costs of revenue were trimmed by -10.07 %, for the same period Beam Therapeutics Inc revnue deteriorated by -94.21 % year on year, sequentially revenue fell by -98.46 %.
Beam Therapeutics, a leading biotechnology company specializing in precision genetic medicines through base editing, has announced significant progress in the manufacturing process for BEAM-101, an investigational base editing therapeutic for sickle cell disease (SCD). The company presented data at the European Hematology Association (EHA) Hybrid Congress, highlighting the success of their closed and automated manufacturing process for base-edited CD34+ hematopoietic stem and progenitor cell (HSPC) genetic medicines. This breakthrough holds promising implications for patients with severe SCD participating in the ongoing BEACON Phase 1/2 clinical trial.Optimized Manufacturing Process for BEAM-101:Beam Therape...
Sources:
Beam Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Beam Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Beam Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
3.52 %